Results 131 to 140 of about 528,594 (306)
β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma
Advanced Science, EarlyView.β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto +20 more
wiley +1 more source
, 2012 Includes bibliographical references.This study is a retrospective cohort analysis of patients undergoing two different treatment modalities (brachytherapy and endoresection) for medium sized choroidal melanoma.
Rice, James C
core
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
Catch me if you can! Novel immune escape mechanisms in melanoma metastases of the brai
, 2018 The immune system is one of the key modulator directing tumor growth and progression, but also therapy responsiveness. Recent reports clearly idicate that drug activity in the brain is not only directed by the drug susceptibility to penetrate the blood ...
Helfrich, I.* +12 more
core
The genetic evolution of melanoma
, 2018 Melanoma tumors are driven by a hyperactivated mitogen-activated protein kinase (MAPK) signalling pathway, and therefore can generally be classified by mutations within the B-Raf proto-oncogene (BRAF), RAS family of proto-oncogenes, neurofibromin 1 (NF1),
Jönsson, Göran, +2 more
core +1 more source
Advanced Science, EarlyView.The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang +10 more
wiley +1 more source
Advanced Science, EarlyView.This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey +6 more
wiley +1 more source
Dermatologic Clinics, 1998 Melanoma vaccines are now an accepted but still experimental treatment for patients who have been rendered clinically free of disease by surgical resection but are at high risk of recurrence and in selected patients with advanced but still limited disease. In general, there seems to be a correlation between the ability of melanoma vaccines to stimulate
openaire +2 more sources
Progression to invasive melanoma frommalignant melanoma in situ, lentigo maligna type
, 2017 We have previously hypothesized that lesions that have been termed lentigo maligna can be divided into 2 categories: 1 represents a pigmented lesion that is a precursor to melanoma, and the other melanoma in situ.
Tannous, Zeina +4 more
core +1 more source
XXX Italian Melanoma Intergroup National Congress | 27-29 September 2024, Rimini, Italy
Dermatology Reportss from the Italian Melanoma Intergroup (IMI) XXX National ...
Italian Melanoma Intergroup (IMI)
doaj +1 more source